Inclusion Criteria

Inclusion Criteria

Concurrent Medication:

Required:

- Zidovudine (AZT), didanosine (ddI), dideoxycytidine (ddC), or a combination thereof,
at current dosage for the 8 weeks of study treatment.

- Prophylaxis (e.g., aerosolized pentamidine, trimethoprim / sulfamethoxazole (TMP /
SMX), dapsone for Pneumocystis carinii pneumonia (PCP) if CD4 cell count is < 200
cells/mm3

Allowed:

- Concurrent maintenance therapy for opportunistic infections.

Prior Medication: Required:

- Zidovudine (AZT), didanosine (ddI), dideoxycytidine (ddC), or a combination thereof,
for at least 2 months.

Patients must have the following:

- Diagnosis of AIDS.

- Documented HIV seropositivity.

- Ability to give informed consent and willingness to comply with visit schedule and
all procedures.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

- Lymphoma or visceral Kaposi's sarcoma.

- Active peptic ulcer or bleeding disorder.

- Hemophilia. Known intolerance to pentoxifylline, theophylline, or caffeine.

Concurrent Medication:

Excluded:

- Warfarin and heparin.

- Biological response modifiers (e.g., erythropoietin, interferon, G-CSF, GM-CSF).

Cytotoxic chemotherapy.

- Megestrol acetate. Corticosteroids.

Concurrent Treatment:

Excluded:

- Radiation therapy. Blood products or transfusions.

Patients with the following are excluded:

- Presence of an active opportunistic infection.

- Major surgery within 30 days of study treatment.

Prior Medication:

Excluded:

- Biological response modifiers (including interferon, interleukin), corticosteroids,
or megestrol acetate within 14 days of first (screening) TNF level.

- Erythropoietin dependency or within 30 days of study treatment.

Prior Treatment:

Excluded:

- Transfusion or blood product dependency or use within 30 days of study treatment.